Literature DB >> 15808913

Brain mast cells and therapeutic potential of vasoactive intestinal peptide in a Parkinson's disease model in rats: brain microdialysis, behavior, and microscopy.

Neşe Tunçel1, Erol Sener, Cem Cerit, Umut Karasu, Firdevs Gürer, Varol Sahintürk, Cengiz Bayçu, Dilek Ak, Zeynep Filiz.   

Abstract

In the present study, the effect of systemically administered vasoactive intestinal peptide (VIP) (25 ng/kg i.p.) was investigated on drug-induced rotational behavior, extra-cellular dopamine levels and histology of corpus striatum in a 6-hydroxydopamine (6-OHDA)-induced rat model of Parkinson's disease. After 15 days of 6-OHDA lesion, apomorphine-induced (0.05 mg/kg s.c.) rotational behavior of the animals significantly increased and extra-cellular dopamine levels of corpus striatum were significantly reduced. VIP reversed the rotational deficits but did not alter the decrease in striatal dopamine levels. On the other hand, histological data indicate that VIP significantly reduced neuronal death and demyelination. Electron microscopic appearance of mast cells showed ultra-structural variety between VIP-treated and 6-OHDA lesioned groups. VIP activates mast cells without any evidence of typical exocytosis, and possibly mast cells could participate in neuroprotection. Our results suggest that systemically administered VIP can attenuate the motor response changes, neuronal cell death, and myelin sheet loss characteristically associated with 12 microg 6-OHDA administration into the rat striatum. Brain mast cells seem to participate in neuronal protection. Possibly, protective cues could be produced by brain mast cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15808913     DOI: 10.1016/j.peptides.2004.12.019

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  15 in total

Review 1.  Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease.

Authors:  Bin Liu
Journal:  AAPS J       Date:  2006-09-29       Impact factor: 4.009

2.  Antioxidant and anti-apoptotic activity of vasoactive intestinal peptide (VIP) against 6-hydroxy dopamine toxicity in the rat corpus striatum.

Authors:  Neşe Tunçel; Orhan Tansel Korkmaz; Neslihan Tekin; Erol Şener; Fahrettin Akyüz; Mine Inal
Journal:  J Mol Neurosci       Date:  2011-08-18       Impact factor: 3.444

3.  Vasoactive intestinal peptide enhances striatal plasticity and prevents dopaminergic cell loss in Parkinsonian rats.

Authors:  OrhanTansel Korkmaz; Hakan Ay; Emel Ulupinar; Neşe Tunçel
Journal:  J Mol Neurosci       Date:  2012-04-29       Impact factor: 3.444

Review 4.  Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders.

Authors:  Caitlin M White; Sunggoan Ji; Huan Cai; Stuart Maudsley; Bronwen Martin
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-11       Impact factor: 4.388

5.  Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells.

Authors:  Orhan Tansel Korkmaz; Neşe Tunçel; Muzaffer Tunçel; Elif Mine Oncü; Varol Sahintürk; Mustafa Celik
Journal:  J Mol Neurosci       Date:  2009-12-02       Impact factor: 3.444

6.  The effects of vasoactive intestinal peptide on dura mater nitric oxide levels and vessel-contraction responses in sympathectomized rats.

Authors:  Fatma Tore; Orhan Tansel Korkmaz; Dilek Dogrukol-Ak; Nese Tunçel
Journal:  J Mol Neurosci       Date:  2009-11-20       Impact factor: 3.444

7.  Inflammatory cells and cytokines in the olfactory bulb of a rat model of neuroinflammation; insights into neurodegeneration?

Authors:  Marie-Francoise Doursout; Michael S Schurdell; Lauren M Young; Uzondu Osuagwu; Diana M Hook; Brian J Poindexter; Mya C Schiess; Diane L M Bick; Roger J Bick
Journal:  J Interferon Cytokine Res       Date:  2013-04-19       Impact factor: 2.607

8.  Modulation of Corpus Striatal Neurochemistry by Astrocytes and Vasoactive Intestinal Peptide (VIP) in Parkinsonian Rats.

Authors:  İbrahim Halil Yelkenli; Emel Ulupinar; Orhan Tansel Korkmaz; Erol Şener; Gökhan Kuş; Zeynep Filiz; Neşe Tunçel
Journal:  J Mol Neurosci       Date:  2016-04-26       Impact factor: 3.444

9.  Transcriptional modulation by VIP: a rational target against inflammatory disease.

Authors:  Hiba Ibrahim; Paul Barrow; Neil Foster
Journal:  Clin Epigenetics       Date:  2011-05-18       Impact factor: 6.551

10.  Dopaminergic Toxin 1-Methyl-4-Phenylpyridinium, Proteins α-Synuclein and Glia Maturation Factor Activate Mast Cells and Release Inflammatory Mediators.

Authors:  Duraisamy Kempuraj; Ramasamy Thangavel; Evert Yang; Sagar Pattani; Smita Zaheer; Donna A Santillan; Mark K Santillan; Asgar Zaheer
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.